Ascites Market

Market Overview:

The 7 major ascites markets reached a value of US$ 1.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1.6 Billion by 2034, exhibiting a growth rate (CAGR) of 3.46% during 2024-2034.

The ascites market has been comprehensively analyzed in IMARC's new report titled "Ascites Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ascites is an abdominal swelling caused by an abnormal buildup of fluid within the peritoneal cavity. This disease can restrict patients from moving around comfortably and increase the likelihood of abdominal infections. In severe cases, the fluid may accumulate in the chest and surround the lungs. The common symptoms associated with the disorder include increased abdominal size, weight gain, shortness of breath, sense of fullness or heaviness, bloating, nausea or indigestion, vomiting, swelling in the lower legs, hemorrhoids, etc. Individuals suffering from this condition may also experience difficulty sitting, fatigue, and constipation. Diagnosing the ailment involves a combination of the patient's medical history, underlying symptoms, and a physical examination. The healthcare provider may perform certain diagnostic tests, including ultrasound and computerized tomography scans, to confirm a diagnosis. Additionally, paracentesis, which involves the insertion of a needle or catheter into the peritoneal cavity, is also utilized to determine the underlying cause.

The increasing cases of liver cirrhosis, which causes a decline in hepatic function, are primarily driving the ascites market. In addition to this, the rising incidences of several associated risk factors, including excessive alcohol consumption, fatty liver disease, various infections, severe malnutrition, lymphatic disorders, etc., are also bolstering the market growth. Furthermore, the widespread adoption of diuretics, like furosemide and spironolactone, for treating the ailment is acting as another significant growth-inducing factor. These drugs increase the amount of water and salt leaving the body, which relieves pressure within the veins around the liver. Additionally, several key players are making investing in R&D activities to launch novel treatment alternatives that can ease symptoms with minimal side effects. This, in turn, is further augmenting the market growth. Moreover, the escalating demand for transjugular intrahepatic portosystemic shunt (TIPS), which involves inserting a wire mesh into the liver vein to treat fluid buildup, is also creating a positive outlook for the market. Apart from this, the emerging popularity of automated low-flow pumps on account of their numerous benefits, including improved symptom relief, more controlled and gradual fluid removal, reduced risk of complications, etc., is expected to drive the ascites market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the ascites market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for ascites and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the ascites market in any manner.

Recent Developments:

• In January 2024, Sequana Medical NV reported that the US Food and Drug Administration accepted their alfapump Premarket Approval (PMA) application for substantive examination. The alfapump is the company's fully implanted, wirelessly charged device for individuals with recurrent or refractory ascites caused by liver cirrhosis.
• In December 2023, Ocelot Bio, Inc. reported that its lead candidate, OCE-205, has been awarded Orphan Drug Designation by the United States FDA for the treatment of ascites caused by all etiologies other than cancer.
• In November 2023, BioVie Inc. announced encouraging clinical safety data from the Company's Phase 2b open-label research assessing the efficacy and safety of BIV201, terlipressin delivered as a continuous infusion, with the standard of care in patients with refractory ascites due to cirrhosis.

Key Highlights:

• The incidence of ascites is around 60,000 per 100,000 people with cirrhosis worldwide.
• Of patients who have ascites, 8,000 to 35,000 would have spontaneous bacterial peritonitis per 100,000 people.
• The incidence of chylous ascites is about 5 per 100,000 people worldwide.
• Patients that advance to refractory ascites experience a one-year survival rate of approximately 50%.
• Patients with cirrhotic ascites exhibited a 3-year death rate of around 50%.

Drugs:

BIV201 refers to a continuous infusion of terlipressin, a medication used to treat the complications of liver cirrhosis. BIV201 is administered utilizing the Company’s patent-pending liquid formulation of terlipressin in a prefilled syringe format as a continuous low-dose infusion with a portable pump.

OsrHSA, derived from the OryzoHiExp platform, has the potential to replace plasma-extracted human serum albumin, which is widely used in the clinical treatment of cirrhosis ascites. The usage of OsrHSA can also eliminate the possibility of HIV, hepatitis, and other viral infections.

PHIN-214 is a SC medication that treats refractory ascites. This derivative of Terlipressin reduces ascites development by lowering portal pressure.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the ascites market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the ascites market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current ascites marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the ascites market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the ascites market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the ascites market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of ascites across the seven major markets?
• What is the number of prevalent cases (2018-2034) of ascites by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of ascites by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of ascites by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with ascites across the seven major markets?
• What is the size of the ascites patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of ascites?
• What will be the growth rate of patients across the seven major markets?
   

Ascites: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for ascites drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the ascites market?
• What are the key regulatory events related to the ascites market?
• What is the structure of clinical trial landscape by status related to the ascites market?
• What is the structure of clinical trial landscape by phase related to the ascites market?
• What is the structure of clinical trial landscape by route of administration related to the ascites market?